GT200100156A - Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester. - Google Patents

Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.

Info

Publication number
GT200100156A
GT200100156A GT200100156A GT200100156A GT200100156A GT 200100156 A GT200100156 A GT 200100156A GT 200100156 A GT200100156 A GT 200100156A GT 200100156 A GT200100156 A GT 200100156A GT 200100156 A GT200100156 A GT 200100156A
Authority
GT
Guatemala
Prior art keywords
cholesterile
ester
transfer protein
inhibitors
pharmaceutical compositions
Prior art date
Application number
GT200100156A
Other languages
English (en)
Inventor
William John Curatolo
Dwayne Thomas Friesen
Michaael Jon Gumkowski
Douglas Alan Lorenz
James Alan Schriver Nightingale
Roger Benjamin Ruggeri
Ravi Mysore Shanker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22835821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200100156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT200100156A publication Critical patent/GT200100156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARAMACEUTICA QUE COMPRENDE UNA DISPERSION AMORFA DE SOLIDOS DE UN INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE COLESTERIL ESTER Y UN POLIMERO QUE AUMENTA LA CONCENTRACION. ESTA COMPOSCION SIRVE PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS, ENFERMEDAD VASCULAR PERIFERICA, DISLIPIDEMIA, HIPERBETALIPOPROTEINEMIA, HIPOALFALIPOPROTEINEMIA, HIPERCOLESTEROLEMIA, HIPERTRIGLICERIDEMIA, TRASTORNOS CARDIOVASCULARES, ANGINA, ISQUEMIA, ETC.
GT200100156A 2000-08-03 2001-08-01 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester. GT200100156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22327900P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
GT200100156A true GT200100156A (es) 2002-04-23

Family

ID=22835821

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100156A GT200100156A (es) 2000-08-03 2001-08-01 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.

Country Status (39)

Country Link
US (4) US7115279B2 (es)
EP (2) EP1305007B1 (es)
JP (2) JP2004505911A (es)
KR (1) KR100561572B1 (es)
CN (1) CN1458840A (es)
AP (1) AP2001002235A0 (es)
AR (1) AR030570A1 (es)
AT (1) ATE503462T1 (es)
AU (1) AU2914202A (es)
BG (1) BG107456A (es)
BR (1) BR0112828A (es)
CA (1) CA2417755A1 (es)
CR (1) CR6883A (es)
CZ (1) CZ2003224A3 (es)
DE (1) DE60144332D1 (es)
DO (1) DOP2001000224A (es)
DZ (1) DZ3391A1 (es)
EA (1) EA007013B1 (es)
EC (1) ECSP034462A (es)
EE (1) EE200300052A (es)
GT (1) GT200100156A (es)
HN (1) HN2001000175A (es)
HU (1) HUP0300676A2 (es)
IL (1) IL154017A0 (es)
IS (1) IS6688A (es)
MA (1) MA26935A1 (es)
MX (1) MXPA03001035A (es)
NO (1) NO20030506D0 (es)
NZ (1) NZ523680A (es)
OA (1) OA12350A (es)
PA (1) PA8523901A1 (es)
PE (1) PE20020271A1 (es)
PL (1) PL365168A1 (es)
SK (1) SK1032003A3 (es)
SV (1) SV2002000581A (es)
TN (1) TNSN01119A1 (es)
UY (1) UY26864A1 (es)
WO (1) WO2002011710A2 (es)
ZA (1) ZA200300869B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
ATE361758T1 (de) * 2001-06-22 2007-06-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
JP2004534822A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1469829B1 (en) * 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
WO2003063821A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
RU2005103625A (ru) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE389396T1 (de) * 2002-12-20 2008-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
KR20050110017A (ko) * 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
CN1777419B (zh) * 2003-03-17 2010-04-28 日本烟草产业株式会社 Cetp抑制剂的药物组合物
KR100857759B1 (ko) * 2003-03-17 2008-09-09 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1653927B1 (en) * 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
EP1670765A2 (en) * 2003-09-30 2006-06-21 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
DK1759702T3 (da) * 2004-05-26 2009-04-20 Bayardo Arturo Jimenez Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
RU2007135224A (ru) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US20070178152A1 (en) * 2005-11-04 2007-08-02 Shelton Michael C Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CA2641451C (en) * 2006-02-09 2012-10-02 Merck & Co., Inc. Polymer formulations of cetp inhibitors
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1997819A1 (de) 2007-05-25 2008-12-03 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Scopinestern
US8337835B2 (en) * 2009-04-10 2012-12-25 Washington University Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
EP2442791B1 (en) 2009-06-16 2019-11-27 Pfizer Inc. Dosage forms of apixaban
RU2013139701A (ru) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
KR20140011366A (ko) 2011-03-08 2014-01-28 잘리커스 파마슈티컬즈 리미티드 고체 분산체 제형 및 그의 이용방법
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
CN104918608A (zh) * 2012-11-19 2015-09-16 雷迪博士实验室有限公司 Cetp抑制剂的药物组合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299641B1 (en) 1987-07-17 1992-06-10 Dow Corning Corporation A curable composition
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5093371A (en) 1990-07-02 1992-03-03 University Of Iowa Research Foundation Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5474993A (en) 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
GB2305665A (en) 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
JP3290962B2 (ja) * 1997-02-12 2002-06-10 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
DE69824901D1 (de) 1997-04-16 2004-08-05 Univ New Mexico Albuquerque Cholesterin Esterase Inhibitoren
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
WO1999041237A1 (en) 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JP3433417B2 (ja) * 1998-04-02 2003-08-04 トヨタ自動車株式会社 レーダ装置
EA004311B1 (ru) 1998-06-11 2004-02-26 Фармация Энд Апджон Компани Таблетированная фармацевтическая композиция непролонгированного действия
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
JP3924124B2 (ja) 1998-09-25 2007-06-06 ファルマシア・コーポレーション コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン
CA2345108A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
KR100436036B1 (ko) 1999-03-08 2004-06-12 샤단호칭키타사토겐큐쇼 Ｗｋ-5344ａ 물질 및 ｗｋ-5344ｂ 물질 그리고 그의 제조법
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2004534822A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
WO2003000226A2 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ATE389396T1 (de) * 2002-12-20 2008-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer

Also Published As

Publication number Publication date
EP2258352A3 (en) 2013-08-14
US8389011B2 (en) 2013-03-05
OA12350A (en) 2006-05-16
US20120277315A1 (en) 2012-11-01
CN1458840A (zh) 2003-11-26
BR0112828A (pt) 2003-07-01
CZ2003224A3 (cs) 2004-02-18
MXPA03001035A (es) 2003-05-27
WO2002011710A2 (en) 2002-02-14
UY26864A1 (es) 2002-02-28
DOP2001000224A (es) 2002-06-15
AR030570A1 (es) 2003-08-27
ATE503462T1 (de) 2011-04-15
MA26935A1 (fr) 2004-12-20
KR20030026995A (ko) 2003-04-03
US20070282009A1 (en) 2007-12-06
AU2914202A (en) 2002-02-18
HUP0300676A2 (hu) 2003-08-28
PL365168A1 (en) 2004-12-27
EP1305007A2 (en) 2003-05-02
NZ523680A (en) 2004-09-24
EA007013B1 (ru) 2006-06-30
HN2001000175A (es) 2001-10-08
AP2001002235A0 (en) 2001-09-30
DZ3391A1 (fr) 2002-02-14
US20020103225A1 (en) 2002-08-01
PA8523901A1 (es) 2002-04-25
NO20030506L (no) 2003-01-31
SK1032003A3 (en) 2004-05-04
CA2417755A1 (en) 2002-02-14
SV2002000581A (es) 2002-10-24
EP1305007B1 (en) 2011-03-30
US20060211654A1 (en) 2006-09-21
US8048452B2 (en) 2011-11-01
WO2002011710A3 (en) 2002-05-02
PE20020271A1 (es) 2002-04-08
KR100561572B1 (ko) 2006-03-16
ECSP034462A (es) 2003-03-31
ZA200300869B (en) 2004-04-16
US7115279B2 (en) 2006-10-03
JP2007314573A (ja) 2007-12-06
DE60144332D1 (de) 2011-05-12
EA200300073A1 (ru) 2003-08-28
EP2258352B1 (en) 2015-05-13
CR6883A (es) 2003-11-25
IL154017A0 (en) 2003-07-31
US8197848B2 (en) 2012-06-12
IS6688A (is) 2003-01-16
EP2258352A2 (en) 2010-12-08
EE200300052A (et) 2004-12-15
NO20030506D0 (no) 2003-01-31
BG107456A (bg) 2003-09-30
JP2004505911A (ja) 2004-02-26
TNSN01119A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
GT200100156A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
CR9465A (es) Compuestos mejorados farmacocineticamente
SV2003001103A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester pc10894
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
SV2006002174A (es) Composicion de anticuerpo her2
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
BR0317521A (pt) Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
BRPI0514723A (pt) composições contendo componentes de agonista alfa-2-adrenérgico
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BR0215366A (pt) Formulações transdérmicas adesivas de diclofenac sódico
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
CY1115453T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα ανασταλτικο παραγοντα του ενζυμου ημg-cοα αναγαγασης και ενα ανασταλτικο παραγοντα του ενζυμου γαστρεντερικης λιπασης